Nutriband Founder Returns as CEO to Lead Final Development of Abuse-Deterrent Fentanyl Patch
Nutriband founder Gareth Sheridan has resumed his role as CEO to lead the final development phase of AVERSA Fentanyl, an abuse-deterrent opioid patch with potential peak annual U.S. sales estimated between $80 million and $200 million.
Nutriband Inc. announced that company founder Gareth Sheridan has returned to the chief executive officer position, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the role. Sheridan will guide the company through its final 2025 development framework toward an expected 2026 New Drug Application filing for AVERSA Fentanyl, the company's flagship abuse-deterrent opioid patch.
The leadership transition comes at a critical juncture for the pharmaceutical development company as it advances its proprietary technology toward commercialization. AVERSA Fentanyl is designed specifically to deter misuse and accidental exposure to the potent opioid, addressing a significant public health concern in the ongoing opioid crisis. The product represents a potential breakthrough in pain management safety, with peak annual U.S. sales projections ranging from $80 million to $200 million.
The AVERSA technology platform, which forms the foundation of the company's abuse-deterrent approach, enjoys extensive intellectual property protection across 46 countries including major pharmaceutical markets in the United States, Europe, and Japan. This global patent coverage provides significant competitive advantages and market protection as the company progresses toward regulatory submissions and potential commercialization.
Sheridan's return to the CEO position signals the company's intensified focus on navigating the complex final development stages required for regulatory approval. The 2025 development framework represents the last major phase before the anticipated 2026 NDA filing, a milestone that would position the company for potential market entry in subsequent years. Additional company information and updates are available through the company's investor communications channels at https://ibn.fm/NTRB.
The development of abuse-deterrent formulations has gained increased attention from regulators, healthcare providers, and public health officials seeking solutions to combat opioid misuse. Nutriband's technology platform demonstrates the pharmaceutical industry's ongoing efforts to balance effective pain management with enhanced safety features. The AVERSA technology's adaptability to various transdermal patch applications suggests potential broader applications beyond the initial fentanyl product.
InvestorWire, the communications platform that distributed the announcement, provides specialized wire-grade press release services as part of the Dynamic Brand Portfolio at IBN. The platform focuses on delivering corporate communications solutions through multiple channels including enhanced press release distribution and social media amplification. More information about their services can be found at https://www.InvestorWire.com.